Showing 1,841 - 1,860 results of 7,701 for search '"Beijing"', query time: 0.06s Refine Results
  1. 1841
  2. 1842
  3. 1843
  4. 1844
  5. 1845
  6. 1846
  7. 1847
  8. 1848
  9. 1849
  10. 1850
  11. 1851
  12. 1852
  13. 1853
  14. 1854

    Predicting the Degree of Coronary Artery Stenosis Through Retinal Vascular Characteristics and Minimal Clinical Information by Zhang G, Ding Y, Ma T, Zhou S, Wang B, Chang X, Zeng Y

    Published 2025-02-01
    “…Gong Zhang,1,2 Yaodong Ding,1 Tong Ma,3 Sijin Zhou,3 Bin Wang,3 Xiangang Chang,3 Yong Zeng1 1Department of Cardiology, Beijing Anzhen Hospital, Beijing Institute of Heart, Lung and Blood Vessel Diseases, Capital Medical University, Beijing, People’s Republic of China; 2Department of Cardiology, Capital Medical University Daxing Teaching Hospital, Capital Medical University, Beijing, People’s Republic of China; 3Beijing Airdoc Technology Co., Ltd, Beijing, People’s Republic of ChinaCorrespondence: Yong Zeng, Department of Cardiology, Beijing Anzhen Hospital, Beijing Institute of Heart, Lung and Blood Vessel Diseases, Capital Medical University, Beijing, People’s Republic of China, Tel +86 135 0137 3114, Email yzeng_anzhen@163.comPurpose: To describe the correlative relationship between fundus vascular characteristics and the severity of coronary artery stenosis.Patients and Methods: A total of 1447 patients scheduled for hospitalization at Beijing Anzhen Hospital Union Hospital for coronary angiography to assess coronary artery conditions between February 2022 and December 2022 were selected. …”
    Get full text
    Article
  15. 1855
  16. 1856
  17. 1857
  18. 1858
  19. 1859

    Immunogenicity and safety of a live attenuated varicella vaccine in children aged 1 to 12 years: A double-blind, randomized, parallel-controlled phase III clinical trial in China by Shiyuan Wang, Yang Zhang, Guifan Li, Jinhui Shi, Xianyun Chang, Hao Zhang, Fengcai Zhu, Jingxin Li, Kai Chu, Jinfang Sun

    Published 2025-12-01
    “…This study aimed to evaluate the immunogenicity and safety of the freeze-dried live attenuated varicella vaccine (VarV) developed by Beijing Minhai Biotechnology Co. LTD. in healthy participants aged 1–12 years. …”
    Get full text
    Article
  20. 1860